Drug
Cep 10953
Cep 10953: highest development phase Phase 3, developed by Teva. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| CEP-10953 (Armodafinil) NCT00078312 | Phase 3 | Narcolepsy |
Latest
No recent events.
Follow Cep 10953 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.